Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
The overexpression of myeloid cell leukemia-1 (MCL-1) has been identified in numerous hematologic malignancies and solid tumors. Currently, there are no selective MCL-1 inhibitors. Here, we present a case of left kidney undifferentiated spindle cell sarcoma with MCL-1 amplification. The tumor showed...
Saved in:
Main Authors: | Cheng-Yu Tang, Chueh-Chuan Yen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
Series: | Journal of Cancer Research and Practice |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
by: Yilan Xu, et al.
Published: (2025-02-01) -
A case report of acute promyelocytic leukemia with myeloid sarcoma of the lumbar spine and literature review
by: Yiwen Du, et al.
Published: (2025-01-01) -
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
by: Mariam Markouli, et al.
Published: (2025-01-01) -
Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01) -
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01)